La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Aldeyra Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Aldeyra Therapeutics..

Aldeyra Therapeutics (NASDAQ:ALDX) Azioni, Catena delle Opzioni

Aldeyra Therapeutics

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. The company's product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer.

Aldeyra Therapeutics, Inc. - Common Stock

Aldeyra Therapeutics Inc

Biotech

News

Health Care

General

ALDX

Aldeyra Therapeutics Has Resubmitted New Drug Application To The FDA For Topical Ocular Reproxalap, An Investigational New Drug Candidate, For Signs And Symptoms Of Dry Eye Disease

HC Wainwright &amp; Co. analyst Matthew Caufield reiterates Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) with a Buy and maintains $10 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Aldeyra Therapeutics, Maintains $10 Price Target

Aldeyra Therapeutics Inc.&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) Phase 3 dry eye chamber clinical trial of 0.25% reproxalap ophthalmic solution <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40247202/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reprox" rel="noreferrer noopener">achieves the primary endpoint</a>.
Reproxalap, an investigational new drug candidate for dry eye disease, was statistically superior to the vehicle for the prespecified primary endpoint of ocular discomfort (P=0.004), an FDA-accepted symptom of dry eye disease.
The company enrolled the first patient in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/b38695423/aldeyra-therapeutics-enrolls-first-patient-in-phase-3-clinical-trial-designed-to-enable-potential-" rel="noreferrer noopener">trial in May 2024</a> and concluded the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/b39308148/aldeyra-therapeutics-completes-enrollment-in-phase-3-clinical-trial-of-reproxalap-in-dry-eye-disea" rel="noreferrer noopener">study in June</a>.
In the Phase 3 clinical trial, patients were administered vehicle (the drug product without the active ingredient) before and during exposure to a dry eye chamber in a manner that Aldeyra believes is consistent with the FDA&#8217;s dry eye disease draft guidance.
Qualifying patients were subsequently randomized to receive either reproxalap or vehicle before and during exposure to an additional dry eye chamber.
Of the 132 patients randomized, 66 patients received reproxalap, and 66 received vehicle.
The primary endpoint was ocular discomfort, an FDA-accepted symptom of dry eye disease, from 80 to 100 minutes in the chamber.
The dry eye chamber clinical trial was designed to satisfy the FDA&#8217;s New Drug Application resubmission requirement, identified in the previously received complete response letter, of &#8220;at least one additional adequate and well-controlled study to demonstrate a positive effect on the treatment of <a target="_blank" href="https://www.benzinga.com/general/biotech/23/11/35980906/fda-rejects-aldeyra-therapeutics-dry-eye-disease-candidate-asks-for-additional-study" rel="noreferrer noopener">ocular symptoms of dry eye</a>.&#8221;
Aldeyra says that in patients with dry eye disease, reproxalap is the first investigational drug with pivotal data supporting acute and chronic activity in reducing symptoms and the first investigational drug for chronic administration with pivotal data supporting acute activity in reducing ocular redness.
The potential NDA resubmission is anticipated in 2024. Based on FDA guidance, the resubmission NDA review period is expected to be six months.
No safety signals were observed in the clinical trial, and reproxalap was well tolerated.
No treatment-related discontinuations were reported. Reproxalap has now been studied in over 2,500 patients.
Price Action: ALDX stock is up 34.8% at $4.40 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40254535/fda-approves-expanded-use-of-novartis-rare-disease-drug-fabhalta-for-kidney-disease" target="_blank" rel="noreferrer noopener">FDA Approves Expanded Use Of Novartis&#8217; Rare Disease Drug Fabhalta For Kidney Disease</a>.</li>
</ul>
Photo: Unsplash

Movers

Trading Ideas

Aldeyra's New Eye Drug Shows Positive Results In FDA-Approved Study, Stock Jumps Over 30%

WIIM

Aldeyra Therapeutics shares are trading higher after the company achieved the primary endpoint in its Phase 3 trial for Reproxalap ophthalmic solution in treating dry eye disease. The company anticipates resubmitting its NDA in 2024.

Aldeyra Therapeutics Achieves Primary Endpoint In Phase 3 Trial For Reproxalap Ophthalmic Solution In Treating Dry Eye Disease; Statistically Superior For Ocular Discomfort; NDA Resubmission Anticipated In 2024

Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.aldeyra.com%2F&amp;esheet=54106089&amp;newsitemid=20240807851086&amp;lan=en-US&amp;anchor=Aldeyra+Therapeutics%2C+Inc.&amp;index=1&amp;md5=93cb165caa8e38c7a8b6221d9cf05084">Aldeyra Therapeutics, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) (Aldeyra) today announced it will host a webcast and conference call on Thursday, August 8, 2024, at 9:00 a.m. (ET) to provide top-line results from the Phase 3 dry eye disease clinical trial of reproxalap.
The dial-in numbers are (888) 596-4144 for domestic callers and (646) 968-2525 for international callers. The access code is 7321123. A live audio webcast of the conference call also will be accessible from the "Investors &amp; Media" section of Aldeyra's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.aldeyra.com%2F&amp;esheet=54106089&amp;newsitemid=20240807851086&amp;lan=en-US&amp;anchor=ir.aldeyra.com&amp;index=2&amp;md5=7016903c7a5b490e613fb08b7a6bf252">ir.aldeyra.com</a>.
After the live webcast, the event will remain archived on Aldeyra's website for 90 days.

Events

Aldeyra Therapeutics Schedules Conference Call And Webcast On Thursday, August 8, 2024, At 9:00 a.m. ET To Announce Top-Line Results From The Phase 3 Dry Eye Chamber Clinical Trial Of Reproxalap

Clinical Trial Results and Potential New Drug Application Resubmission Expected in the Second Half of 2024

Aldeyra Therapeutics Wraps Up Phase 3 Trial Enrollment For Reproxalap In Dry Eye Disease

Aldeyra Therapeutics Enrolls First Patient in Phase 3 Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease, Clinical Results and Potential New Drug Application Submission Expected In 2H Of 2024

Oppenheimer analyst Francois Brisebois reiterates Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) with a Outperform and maintains $10 price target.

Oppenheimer Reiterates Outperform on Aldeyra Therapeutics, Maintains $10 Price Target

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day

The Dow Jones index closed lower by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Aldeyra Therapeutics </h3>
<ul>
<li>The Trade: Aldeyra Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aldx#NASDAQ">ALDX</a>) 10% owner Joseph Edelman <a href="https://www.benzinga.com/quote/CALC/analyst-ratings"> acquired a total of 504,272 shares </a> an average price of $3.84. To acquire these shares, it cost around $1.93 million.</li>
<li>What&rsquo;s Happening: On April 3, Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.</li>
<li>What Aldeyra Therapeutics Does: Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases.</li>
</ul>
<h3>Retractable Technologies</h3>
<ul>
<li>The Trade: Retractable Technologies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/rvp#NYSE">RVP</a>) President and CEO Thomas J Shaw <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 8,292 shares at </a> at an average price of $1.15. To acquire these shares, it cost around $9,499.</li>
<li>What&rsquo;s Happening: On March 29, Retractable Technologies reported results for 2023.</li>
<li>What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/earnings/24/04/38084045/levi-strauss-conagra-brands-and-3-stocks-to-watch-heading-into-thursday"> Levi Strauss, Conagra Brands And 3 Stocks To Watch Heading Into Thursday </a>
<h3>Alzamend Neuro </h3>
<ul>
<li>The Trade: Alzamend Neuro, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alzn#NASDAQ">ALZN</a>) Director Milton C Ault III <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 334 shares </a> at an average price of $0.91. The insider spent around $304 to buy those shares.</li>
<li>What&rsquo;s Happening: On Dec. 11, 2023, Alzamend Neuro received a &quot;Study May Proceed&quot; letter from the FDA for the initiation of study AL001-PTSD01, a Phase 2A study of AL001 for post-traumatic stress disorder (PTSD).</li>
<li>What Alzamend Neuro Does: Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer&#39;s.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Long Ideas

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

ALZN

Aldeyra Therapeutics And 2 Other Stocks Under $5 Insiders Are Buying

Aldeyra Therapeutics shares are trading higher after Oppenheimer upgraded the stock from Perform to Outperform and announced a $10 price target.

Oppenheimer analyst Francois Brisebois upgrades Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) from Perform to Outperform and announces $10 price target.

Upgrades

Oppenheimer Upgrades Aldeyra Therapeutics to Outperform, Announces $10 Price Target

HC Wainwright &amp; Co. analyst Matthew Caufield reinstates Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) with a Buy and announces $10 price target.

Initiation

HC Wainwright & Co. Reinstates Buy on Aldeyra Therapeutics, Announces $10 Price Target

Aldeyra Therapeutics shares are trading higher. The company announced the clinical development plan intended to enable resubmission of a New Drug Application for reproxalap in dry eye disease.

Aldeyra Therapeutics Disclosed Clinical Development Plan For Resubmission Of New Drug Application For Reproxalap In Dry Eye Disease

<h3>Gainers</h3>
<ul>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) stock increased by 62.4% to $1.4 during Tuesday's after-market session. The company's market cap stands at $30.6 million. </li>
<li>vTv Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTVT#NASDAQ">VTVT</a>) stock moved upwards by 13.17% to $15.55. The company's market cap stands at $32.4 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock increased by 9.09% to $2.16. The company's market cap stands at $391.3 million. The company's, Q4 earnings came out today. </li>
<li>Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) stock increased by 7.32% to $6.01. The company's market cap stands at $391.4 million. The company's, Q4 earnings came out today. </li>
<li>YS Biopharma Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YS#NASDAQ">YS</a>) stock rose 6.36% to $0.65. The market value of their outstanding shares is at $122.1 million. </li>
<li>Aldeyra Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALDX#NASDAQ">ALDX</a>) shares increased by 6.1% to $4.17. The company's market cap stands at $245.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Heart Test Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSCS#NASDAQ">HSCS</a>) shares decreased by 22.2% to $0.14 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Marinus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNS#NASDAQ">MRNS</a>) stock decreased by 12.56% to $8.08. The company's market cap stands at $440.9 million. As per the press release, Q4 earnings came out today. </li>
<li>Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) shares declined by 10.39% to $1.64. The company's market cap stands at $209.0 million. </li>
<li>Cara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CARA#NASDAQ">CARA</a>) shares decreased by 8.8% to $0.83. The market value of their outstanding shares is at $45.2 million. The company's, Q4 earnings came out yesterday. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) stock fell 8.42% to $10.89. The company's market cap stands at $40.7 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares fell 8.01% to $8.5. The market value of their outstanding shares is at $166.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CARA

CERS

CMAX

CMPX

Envoy Medical, Inc. - Class A Common Stock

COCH

HSCS

MRNS

NKGN

SOPH

VTVT

12 Health Care Stocks Moving In Tuesday's After-Market Session

Aldeyra Therapeutics (ALDX) just unveiled an update. Aldeyra Therapeutics, Inc. has announced the success of its Phase 3 clinical trial for 0.25% r...

Aldeyra Therapeutics Announces Major Dry Eye Treatment Success

Aldeyra climbs after late-stage success for dry eye disease therapy

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Aldeyra Therapeutics (ALDX – Research Report) today and set a price target of $...

Buy Recommendation for Aldeyra Therapeutics Amid Positive Phase 3 Results for Reproxalap

BTIG analyst Thomas Shrader has maintained their bullish stance on ALDX stock, giving a Buy rating today. Thomas Shrader's rating is based on a com...

Aldeyra Therapeutics: A Buy Rating on Strong Clinical Progress and Market Potential

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Xeris Pharmaceuticals (XERS – Research Report), Al...

Analysts Offer Insights on Healthcare Companies: Xeris Pharmaceuticals (XERS), Aldeyra Therapeutics (ALDX) and Immunic (IMUX)

Aldeyra Therapeutics Has Data To Trigger AbbVie Partnership

Undercovered Dozen: United Natural Foods, Procter & Gamble, Archer Aviation, Embraer +

An update from Aldeyra Therapeutics (ALDX) is now available. Aldeyra Therapeutics, Inc. has announced the appointment of Michael Alfieri as the new...

Aldeyra Therapeutics Announces Executive Team Changes

Aldeyra Therapeutics resubmits new drug application for treatment of dry eye disease

Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects

ABBV

ACHR

FMCC

FMCCG

FMCCH

FMCCI

FMCCJ

FMCCK

FMCCL

FMCCM

FMCCN

FMCCO

FMCCP

FMCCS

FMCCT

FMCKI

FMCKJ

FMCKK

FMCKL

FMCKM

FMCKN

FMCKO

FMCKP

FNMA

FNMAG

FNMAH

FNMAI

FNMAJ

FNMAK

FNMAL

FNMAM

FNMAN

FNMAO

FNMAP

FNMAS

FNMAT

FNMFM

FNMFN

FNMFO

FREGP

FREJN

FREJO

FREJP

GLPG

GLPGF

GMAB

GNMSF

IMOS

IMUX

KRKNF

UNFI

XERS

Press Releases

Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease

Legal

Investigation Alert: Aldeyra, Eagle Pharmaceuticals, and Blue Ridge Bankshares: Johnson Fistel, LLP Encourages Long-Term Investors to Submit Their Information Below

Aldeyra Therapeutics Announces Advancement of New RASP Modulators and Recent Preclinical Data in Obesity at 2024 Investor Roundtable

Aldeyra, Eagle Pharmaceuticals, Blue Ridge Bankshares, and Amplitude Investigation Alert: Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information

Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from the Phase 3 Dry Eye Chamber Clinical Trial of Reproxalap

Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Clinical Trial of Reproxalap

Aldeyra Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Aldeyra Therapeutics Resubmits Reproxalap New Drug Application for the Treatment of Dry Eye Disease

Aldeyra Therapeutics Selected to Present at the Disruptive Innovations Symposium during the OSN New York Retina 2024 Meeting

Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Comments

Aldeyra Therapeutics

Aldeyra Therapeutics (ALDX) Opzioni

Aldeyra Therapeutics (NASDAQ:ALDX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO